Carregant...
Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modeling
OBJECTIVES: Lack of data on the pharmacokinetics of efavirenz in pregnant women at the 400 mg reduced dose currently prevents universal roll out. Population pharmacokinetic modeling was used to explore pharmacokinetic end-points at 200, 400, and 600 mg daily doses in pregnant women stratified by CYP...
Guardat en:
| Publicat a: | J Antimicrob Chemother |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7614711/ https://ncbi.nlm.nih.gov/pubmed/29029267 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkx334 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|